Business context and reporting period
Novavax, Inc. is a biotechnology company developing recombinant protein vaccines with its Matrix-M adjuvant. This Form 10-K reports the fiscal year ended December 31, 2023; although the request refers to 2023 Q4, the supplied filing text does not provide clear standalone fourth-quarter financial results. The company’s only commercial program was its COVID-19 vaccine. Its updated 2023–2024 vaccine received U.S. FDA emergency use authorization in October 2023 for people aged 12 and older, and U.S. commercial sales began in the fourth quarter.
Other programs include a COVID-19/influenza combination vaccine in Phase 2 and partner-led R21/Matrix-M malaria vaccine, which received WHO prequalification in December 2023. Novavax earns revenue from COVID-19 vaccine sales, government-funded development work, royalties and Matrix-M adjuvant sales.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Total revenue | $983.7 million | $1,981.9 million |
| Product sales | $531.4 million | $1,555.0 million |
| Grant revenue | $427.3 million | $382.9 million |
| Cost of sales | $343.8 million | $902.6 million |
| Research and development | $737.5 million | $1,235.3 million |
| Selling, general and administrative | $468.9 million | $488.7 million |
| Operating loss | $566.5 million | $644.7 million |
| Net loss | $545.1 million ($5.41 per share) | $657.9 million ($8.42 per share) |
| Cash used in operating activities | $714.0 million | $415.9 million |
| Cash, cash equivalents and restricted cash at year-end | $583.8 million | $1,348.8 million |
Revenue fell $998.2 million, mainly because fewer COVID-19 vaccine doses were sold. Product sales were down $1.024 billion; grant revenue rose $44.4 million, reflecting greater activity under the U.S. government agreement. The company recognized the full $1.8 billion of funding under that agreement in revenue cumulatively. Cost of sales was 65% of product sales, compared with 58% in 2022; it included inventory and purchase-commitment charges, idle manufacturing capacity and other items described below. The filing does not provide a conventional gross-margin measure.
Year-end cash and cash equivalents were $568.5 million, plus $15.3 million of restricted cash. Novavax reported a working-capital deficiency. Total liabilities were $2.514 billion and stockholders’ deficit was $716.9 million. Convertible notes had a $175.3 million face amount, bear 5.00% interest and mature in 2027; their year-end carrying value was $168.0 million. The company repaid $325 million of 3.75% notes in January 2023.
Material changes and unusual items
- Operating expenses declined by approximately $1.1 billion, or 41%, from 2022. R&D decreased by $497.8 million, primarily from lower coronavirus-vaccine manufacturing, support and clinical-study costs.
- FY 2023 cost of sales included $145.9 million of excess, obsolete or expired inventory and firm purchase-commitment losses, $64.0 million of unutilized manufacturing capacity and a $6.1 million embedded-lease impairment; a $40.2 million recovery reflected negotiated reductions in purchase commitments. Separately, reported inventory write-downs were $72.4 million and firm purchase-commitment losses were $73.5 million, partly offset by the $40.2 million recovery.
- U.S. commercial sales generated significant estimated return and distributor deductions: $84.6 million for product returns and $47.0 million for distributor fees, discounts and chargebacks were charged against 2023 sales. The return estimate is a significant judgment, given limited U.S. commercial sales history.
- The company paid SK bioscience $149.8 million under a settlement relating to canceled manufacturing work and recorded a net gain from the combined settlement and stock-placement arrangement. Novavax also issued 52.8 million shares through at-the-market sales and related stock issuances during 2023, raising approximately $367 million net in total, including the SK placement.
- Novavax recorded $14.6 million of 2023 restructuring charges. A further workforce reduction announced in January 2024 was expected to cost $4–$7 million in severance; management expected about 85% of its annual savings impact, excluding one-time charges, in 2024.
Outlook, risks and contingencies
Management expects 2024 R&D expense to decrease from 2023 as it reduces manufacturing footprint and spending, and as certain manufacturing costs qualify for inventory capitalization. The company gave no numerical 2024 revenue guidance in the supplied filing text. Revenue depends heavily on the 2024–2025 COVID-19 season, regulatory authorization, demand, timely supply and market acceptance, including whether a single-dose vial or prefilled syringe presentation can be introduced. Management targeted a pivotal Phase 3 trial of the combination vaccine in the second half of 2024, subject to FDA concurrence, with a potential 2026 launch.
Going concern: Management and the auditor stated that substantial doubt exists about Novavax’s ability to continue as a going concern for at least one year after issuance of the financial statements. The company cited recurring losses, negative working capital, cash burn and uncertainty about 2024 revenue and cost reductions. Management’s plans include restructuring, commercial execution and potential additional financing, but financing may not be available on acceptable terms or at all.
- Gavi settlement, subsequent event: On February 16, 2024, Novavax settled the Gavi APA arbitration. It paid $75 million on February 20 and agreed to $400 million of deferred payments, in annual amounts of $80 million through 2028. Qualifying vaccine sales credits may reduce deferred payments; an additional credit of up to $225 million may apply to qualifying sales above the annual payment amount. At year-end 2023, $696.4 million related to the disputed advance payment was classified as a current liability; the settlement occurred after year-end.
- Canada APA: The Canadian government received doses and paid a contingent $174.8 million installment in January 2024. It may terminate the amended agreement if bulk antigen made at the Biologics Manufacturing Centre is not approved by December 31, 2024. Novavax said its 2024 plans did not anticipate seeking that approval and that it would pursue an amendment. Termination could make $28 million of deferred revenue refundable and put approximately $224 million of future contract value at risk.
- Australia APA: In February 2024, the Australian government purported to cancel an order; Novavax disputes the cancellation. If it is permitted, $6 million of deferred revenue would become a credit toward future deliveries and about $48 million of future contract value would be lost. The dispute follows a vaccine lot removed from the Australian market after stability testing; Novavax recorded a $64.7 million credit against future sales.
- Other contractual exposure: Novavax was discussing treatment of a remaining $112.5 million UK upfront payment, recorded in other current liabilities, after the UK advisory committee did not make the required supportive recommendation. A Fujifilm arbitration concerns two withheld installments totaling $68.6 million; the balance was accrued, and a hearing was scheduled for May 2024.
- Litigation: A securities class action had a proposed $47 million settlement, expected to be funded by directors’ and officers’ insurance, pending final court approval scheduled for May 2024. Related derivative litigation remained pending or stayed; its financial impact was not estimable.
- Commercial and operating risks include competition from larger vaccine makers, uncertain COVID-19 demand and variants, reliance on external manufacturers and distributors, regulatory and manufacturing delays, product returns and inventory obsolescence, and the need for additional capital. The company also disclosed a history of losses and a $4.8 billion accumulated deficit.
Important facts for investors to verify
- Quarterly results and U.S. commercial sales, net of returns, discounts and chargebacks; the supplied text gives annual totals but no clear standalone Q4 figures.
- Cash runway and cash burn after the Gavi settlement payments, the January Canada receipt, and any additional financing or share issuance.
- Progress on 2024–2025 vaccine authorization, single-dose or prefilled-syringe presentation, manufacturing readiness and customer demand.
- Resolution of the Canada and Australia APA issues and the UK upfront-payment liability, including any refunds or lost contract value.
- Actual realization of restructuring savings and the impact of inventory write-downs, purchase commitments and manufacturing capacity on future cost of sales.
- Final approval of the securities class-action settlement and developments in derivative litigation and the Fujifilm arbitration.